Press releases

3 March, 2025

Regulatory

Delisting of the shares of Abliva: last day of trading 17 March 2025

In accordance with Nasdaq Stockholm AB’s decision, following an application from the Board of Directors of Abliva AB (publ), the shares of Abliva will be delisted from Nasdaq Stockholm. The [&he ...

25 February, 2025

Regulatory

Abliva applies for delisting and will convene an extraordinary general meeting

The outcome of the extended acceptance period in the public offer from Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., regarding Abliva AB (publ) ...

15 June, 2020

Regulatory

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...

31 October, 2018

Regulatory

NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1

Lund, Sweden October 31 2018 – NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or ”the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces today that the subscription period for the warrants of ...

29 May, 2018

Regulatory

Information regarding trading of warrants issued by NeuroVive

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...

2 June, 2016

Regulatory

NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...

23 May, 2016

Regulatory

Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...

26 June, 2015

Regulatory

NeuroVive share upgraded on OTC market in US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade ...

11 February, 2015

Regulatory

New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan

NeuroVive has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is sourced from Taiwanese investors, collabor ...

10 April, 2014

Regulatory

Abliva

Press releases

Delisting of the shares of Abliva: last day of trading 17 March 2025

Abliva applies for delisting and will convene an extraordinary general meeting

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1

Information regarding trading of warrants issued by NeuroVive

NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US

Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive share upgraded on OTC market in US

New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan

NeuroVive Stock Now Trading in the USA on the OTC Market

NeuroVive First Day of Trading on NASDAQ OMX Stockholm

NeuroVive: NeuroVive Admitted to Trading on NASDAQ OMX Stockholm